Opens in a new tab

Edwards Lifesciences v Meril Life Sciences (CFI, ORD_16663/2024, 20 August 2024)

Date20 August 2024
CourtCFI
DivisionNordic Baltic Regional Division
Type of actionGeneric application
Registry referenceApp_14299/2024 · ORD_16663/2024
PartiesMERIL LIFE SCIENCES PVT LIMITED, INTERLUX, UAB, SMIS INTERNATIONAL OÜ, MERIL GMBH, SORMEDICA, UAB, VAB-LOGISTIK, UAB

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 20 August 2024 (UPC_CFI_380/2023, ACT_582093/2023, ORD_16663/2024), the Nordic-Baltic Regional Division (Johansson, Härmand, Bessaud, Wilhelm) dismissed the request of Meril Life Sciences and five other defendants to stay the infringement action on EP 3 769 722 brought by Edwards Lifesciences pending the decision of the EPO Opposition Division. Leave to appeal was granted.

Question

Should the division stay proceedings during an EPO opposition, on the basis of Rule 118.2(b) RoP, Art. 33(10) UPCA or Rule 295 RoP?

Decision

No. Rule 118.2(b) RoP, located in the chapter on the oral procedure, cannot found a stay during the written procedure (paragraphs 4 to 6). The primary provisions are Art. 33(10) UPCA and Rule 295(a) RoP, which require that a rapid EPO decision be expected (paragraph 7). That is not so: the opposition was filed on 7 March 2024 and the Opposition Division’s decision would probably be appealed, adding 18 to 24 months (paragraph 8). Rule 295(m) RoP must respect those specific provisions and the right to a hearing within a reasonable time (paragraphs 9 to 11). As a rule, the division will not stay where a final EPO decision is not expected rapidly, even if invalidity is highly likely (paragraph 12), all the more so as the UPC will itself decide the counterclaims for revocation (paragraph 13). The auxiliary request under Art. 33(3) UPCA is dismissed, as no bifurcation is envisaged (paragraph 16).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts. 33(3) and (10) and 73(2)(b)(ii)
Rules of Procedure
Rules 37, 118.2(b), 220.2, 224.1(b) and 295
Case law cited
Carrier v BITZER Electronics, Court of Appeal, 28 May 2024

Related decisions

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Written procedure (UPC), Court fees and costs (UPC).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Generic application
Outcome (Dhenne Avocats summary)
La demande de sursis à statuer dans l'attente de la décision de la division d'opposition de l'OEB est rejetée, aucune décision définitive rapide n'étant attendue. L'appel est autorisé.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 769 722
Low profile delivery system for transcatheter heart valve
recorded proprietor: Edwards Lifesciences Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 9 other decision(s): Edwards Lifesciences v Meril Life Sciences (CFI, 21 July 2025) · Edwards Lifesciences v Meril Life Sciences (CFI, 12 May 2026) · EDWARDS LIFESCIENCES v MERIL LIFE SCIENCES (CFI, 5 December 2025) · Edwards Lifesciences v Meril Life Sciences (CFI, 2 September 2025) · Edwards Lifesciences v Meril Life Sciences (CFI, 21 January 2025) · Meril Life Sciences v Edwards Lifesciences (CFI, 11 December 2024) · EDWARDS LIFESCIENCES v MERIL LIFE SCIENCES (CFI, 10 December 2024) · Meril Life Sciences v Edwards Lifesciences (CoA, 21 November 2024)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.